Navigation Links
VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
Date:8/25/2008

BOSTON, Aug. 25 /PRNewswire/ -- Scimitar Equity, LLC issues a review of VioQuest Pharmaceuticals, Inc (OTC Bulletin Board: VOQP), entitled, "Creating Value; Turnaround Leverages Product Opportunities while Expectation Abounds and Losses Decrease."

This review is available at website: http://www.scimitarequity.com

VioQuest Pharmaceuticals is a New Jersey-based biotechnology company dedicated to becoming a recognized leader in the successful development of novel drug therapies targeting both the molecular basis of cancer and side effects of treatment. VioQuest's oncology portfolio includes: Xyfid(TM) (1% uracil topical), for the treatment of dry skin conditions and manage the burning and itching associated with various dermatoses; VQD-002 (triciribine phosphate monohydrate), a targeted inhibitor of Akt activation; and Lenocta(TM) (sodium stibogluconate), an inhibitor of certain protein tyrosine phosphatases such as SHP-1, SHP-2, and PTP1B. Further information about VioQuest can be found at: http://www.vioquestpharm.com

Scimitar Equity, LLC provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about VioQuest Pharmaceuticals, Inc (OTC Bulletin Board: VOQP) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.

CONTACT: Scimitar Equity, LLC

Henry W. McCusker

Director of Research

phone: (617) 559.1080

e-mail: hwm@scimitarequity.com


'/>"/>
SOURCE Scimitar Equity, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
2. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
3. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
6. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
7. Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
8. Alseres Pharmaceuticals, Inc. Raises $5 Million
9. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
10. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
11. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017 Research and Markets has ... and Global Markets" report to their offering. ... The study ... sequencing, biochips, RNA interference, synthetic biology tools and genome editing ... These technologies and products are analyzed to determine ...
(Date:3/28/2017)... ... 2017 , ... NetDimensions announced today that Scandinavian Health Limited ... management for consistent implementation of standards and regulatory requirements across SHL companies worldwide. ... improve and streamline their training and employee development programs, which are critical to ...
(Date:3/28/2017)... ... March 28, 2017 , ... Benchworks announced that ... Philadelphia. The event was offered by the Chamber of Commerce for Greater Philadelphia ... groups and interaction with speakers who are leaders in their industries. Topics included ...
(Date:3/28/2017)... March 28, 2017 Summary This ... Enzo Biochem and its partnering interests and activities since 2010. ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ... The report will be delivered in PDF format ...
Breaking Biology Technology:
(Date:3/23/2017)... report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and Touchless), Product ... by MarketsandMarkets, the market is expected to be worth USD 18.98 billion by ... Continue Reading ... ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
(Date:3/13/2017)... -- Future of security: Biometric Face Matching software  ... ... Face Matching enables to match face pictures against each other or against large ... Identification Systems) ... is the fastest software for biometric Face Matching on the market. The speed ...
Breaking Biology News(10 mins):